智通财经APP讯，先健科技(01302)发布公告，于2026年5月22日，公司拟向卖方AUT-VII HK Holdings Limited收购北京华医圣杰科技有限公司(华医)约96.46%股权。交易代价约为人民币18.733亿元。代价将由公司向卖方发行可换股债券予以支付。交割后，华医将成为公司的非全资附属公司，其财务业绩将并入集团的综合财务报表。
作为一家医疗器械公司，华医主要从事血管介入医疗器械的研发、制造及销售。华医的产品主要用于治疗先天性心脏缺损及预防心因性栓塞性中风。华医于2003年在中国推出首批国产先天性心脏病封堵器之一，并于2009年推出中国首个卵圆孔未闭(PFO)封堵器产品。
华医主要从事血管介入医疗器械的研发、制造及销售，在专有技术、市场准入及研发能力方面具备竞争优势。董事认为，收购华医符合集团的整体发展策略，并将为公司带来长远的裨益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.